Program
orticumab
Also written as “MLDL1278A” and “Orticumab”.
Its studies are mostly in Psoriasis · Acute Coronary Syndrome · Atherosclerosis, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Abcentra | 21 open or running | phase 2since Feb 16, 2021 | Feb 16, 2021 | Feb 8, 2027phase 2 · NCT06927739 |
| BioInvent International AB | 10 open or running | phase 1since Nov 22, 2011 | Nov 22, 2011 | none ahead |
| Hoffmann-La Roche | 10 open or running | phase 2since Dec 10, 2010 | Dec 10, 2010 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 10, 2010First study: phase 2 study in AtherosclerosisNew to Hoffmann-La RocheHoffmann-La Roche · NCT01258907 · 147 enrolled · United States, Canada
- Nov 22, 2011BioInvent International AB's first study: phase 1 study in HealthyNew to BioInvent International ABBioInvent International AB · NCT01486823 · 22 enrolled · United Kingdom
- Feb 16, 2021Abcentra's first study: phase 2 study in PsoriasisNew to AbcentraAbcentra · NCT04776629 · 77 enrolled · United States
- Mar 25, 2025Phase 2 study in Acute Coronary SyndromeAbcentra · NCT06927739 · 240 planned · United States, Czechia, Hungary and more
Ahead
- Feb 8, 2027Primary completion: phase 2 study in Acute Coronary SyndromeAbcentra · NCT06927739
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06927739Acute Coronary Syndrome · United States, Czechia, Hungary and more | 2 | Recruiting | Abcentra | Feb 8, 2027 | 240 |
| NCT04776629Psoriasis · United States | 2 | Completed | Abcentra | Nov 11, 2022 | 77 |
| NCT01486823Healthy · United Kingdom | 1 | Completed | BioInvent International AB | Jul 2012 | 22 |
| NCT01258907Atherosclerosis · United States, Canada | 2 | Completed | Hoffmann-La Roche | Jul 2012 | 147 |
How it is read
Names in the registry
- “MLDL1278A”, 4 entries
- “Orticumab”, 2 entries
Conditions, from the studies’ own filings
- Psoriasis, 1 study
- Acute Coronary Syndrome, 1 study
- Atherosclerosis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.